معرفی
Dipongkor Saha, DVM, PhD, is an Associate Professor in Cancer Biology at North Carolina A&T State University. He is also a UNC Lineberger Comprehensive Cancer Center member with research interests focused on breast and brain cancer immunology and immunotherapy. Dr. Saha has established research programs in glioblastoma (GBM) and triple-negative breast cancer (TNBC), with a particular focus on oncolytic virus-based immunotherapies.
Dr. Saha's research interests encompass cancer immunology, immunotherapy, and the use of oncolytic viruses and cancer vaccines to treat cancers. His work specifically focuses on developing immunovirotherapy approaches for difficult-to-treat cancers like glioblastoma and triple-negative breast cancer. His research program integrates tumor immunology, oncolytic adenoviruses, adoptive T-cell therapy, and animal models of cancer, with a particular emphasis on engineering oncolytic herpes simplex virus (oHSV)-based immunotherapy for GBM treatment.
Analysis of Dr. Saha's recent publications reveals a clear research trajectory focused on advancing oncolytic virus immunotherapy, particularly for brain and breast cancers. His work demonstrates increasing sophistication in engineering viral vectors (particularly herpes simplex and adenovirus platforms) to deliver immunomodulatory molecules like interleukins. The research consistently targets challenging cancers like glioblastoma and triple-negative breast cancer, with recent work expanding into ovarian cancer applications. A notable trend is the combination of oncolytic viruses with other immunotherapeutic approaches like checkpoint blockade and T-cell engagers.
Dr. Saha has developed extensive collaborations with both on- and off-campus investigators, including cancer immunology (Dr. Holloman), TNBC biology (Dr. Rorie), breast cancer virology (Dr. Muganda), synthetic virus constructs (Dr. Newman), neuroscience (Drs. Cannady and Niere), evolutionary biology (Dr. Graves), and radiation oncology (Dr. Nolan). He also maintains strong collaborative relationships with clinician-scientists at Harvard Medical School, Massachusetts General Hospital, and the University of Helsinki.
